154 related articles for article (PubMed ID: 27643557)
1. Discovery of novel antagonists of human neurotensin receptor 1 on the basis of ligand and protein structure.
Zhang G; Wang K; Li XD; Zhang DL; Xu F
Biomed Pharmacother; 2016 Dec; 84():147-157. PubMed ID: 27643557
[TBL] [Abstract][Full Text] [Related]
2. [Establishment and application of human CHO/NTR1 system].
Zhang G; Sun T; Liu HJ; Niu GJ; Xu F
Yao Xue Xue Bao; 2014 Sep; 49(9):1273-8. PubMed ID: 25518326
[TBL] [Abstract][Full Text] [Related]
3. A single amino acid of the human and rat neurotensin receptors (subtype 1) determining the pharmacological profile of a species-selective neurotensin agonist.
Cusack B; Jansen K; McCormick DJ; Chou T; Pang Y; Richelson E
Biochem Pharmacol; 2000 Sep; 60(6):793-801. PubMed ID: 10930533
[TBL] [Abstract][Full Text] [Related]
4. Intermolecular cross-talk between NTR1 and NTR2 neurotensin receptor promotes intracellular sequestration and functional inhibition of NTR1 receptors.
Hwang JR; Baek MW; Sim J; Choi HS; Han JM; Kim YL; Hwang JI; Kwon HB; Beaudet N; Sarret P; Seong JY
Biochem Biophys Res Commun; 2010 Jan; 391(1):1007-13. PubMed ID: 19968961
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist.
Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN
J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555
[TBL] [Abstract][Full Text] [Related]
6. The amide linker in nonpeptide neurotensin receptor ligands plays a key role in calcium signaling at the neurotensin receptor type 2.
Thomas JB; Giddings AM; Olepu S; Wiethe RW; Warner KR; Sarret P; Longpre JM; Runyon SP; Gilmour BP
Bioorg Med Chem Lett; 2015; 25(10):2060-4. PubMed ID: 25881832
[TBL] [Abstract][Full Text] [Related]
7. SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands.
Huber S; Casagrande F; Hug MN; Wang L; Heine P; Kummer L; Plückthun A; Hennig M
PLoS One; 2017; 12(5):e0175842. PubMed ID: 28510609
[TBL] [Abstract][Full Text] [Related]
8. Virtual screening of a natural compound library at orthosteric and allosteric binding sites of the neurotensin receptor.
Rejwan Ali M; Sadoqi M; Boutajangout A; Mezei M
J Biomol Struct Dyn; 2019 Oct; 37(17):4494-4506. PubMed ID: 30479178
[TBL] [Abstract][Full Text] [Related]
9. A novel identification approach for discovery of 5-HydroxyTriptamine 2A antagonists: combination of 2D/3D similarity screening, molecular docking and molecular dynamics.
Kumar R; Jade D; Gupta D
J Biomol Struct Dyn; 2019 Mar; 37(4):931-943. PubMed ID: 29468945
[TBL] [Abstract][Full Text] [Related]
10. Proposed ligand binding site of the transmembrane receptor for neurotensin(8-13).
Pang YP; Cusack B; Groshan K; Richelson E
J Biol Chem; 1996 Jun; 271(25):15060-8. PubMed ID: 8663052
[TBL] [Abstract][Full Text] [Related]
11. Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.
Härterich S; Koschatzky S; Einsiedel J; Gmeiner P
Bioorg Med Chem; 2008 Oct; 16(20):9359-68. PubMed ID: 18809332
[TBL] [Abstract][Full Text] [Related]
12. Mutagenesis and modeling of the neurotensin receptor NTR1. Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist.
Labbé-Jullié C; Barroso S; Nicolas-Etève D; Reversat JL; Botto JM; Mazella J; Bernassau JM; Kitabgi P
J Biol Chem; 1998 Jun; 273(26):16351-7. PubMed ID: 9632698
[TBL] [Abstract][Full Text] [Related]
13. In Silico Investigation of the Neurotensin Receptor 1 Binding Site: Overlapping Binding Modes for Small Molecule Antagonists and the Endogenous Peptide Agonist.
Lückmann M; Holst B; Schwartz TW; Frimurer TM
Mol Inform; 2016 Jan; 35(1):19-24. PubMed ID: 27491650
[TBL] [Abstract][Full Text] [Related]
14. Neurotensin negatively modulates Akt activity in neurotensin receptor-1-transfected AV12 cells.
Liu F; Yang P; Baez M; Ni B
J Cell Biochem; 2004 Jun; 92(3):603-11. PubMed ID: 15156571
[TBL] [Abstract][Full Text] [Related]
15. The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.
Thomas JB; Navarro H; Warner KR; Gilmour B
Bioorg Med Chem Lett; 2009 Mar; 19(5):1438-41. PubMed ID: 19195889
[TBL] [Abstract][Full Text] [Related]
16. Flexi-pharma: a molecule-ranking strategy for virtual screening using pharmacophores from ligand-free conformational ensembles.
Lans I; Palacio-Rodríguez K; Cavasotto CN; Cossio P
J Comput Aided Mol Des; 2020 Oct; 34(10):1063-1077. PubMed ID: 32656619
[TBL] [Abstract][Full Text] [Related]
17. Discovery of high affinity ligands for β2-adrenergic receptor through pharmacophore-based high-throughput virtual screening and docking.
Yakar R; Akten ED
J Mol Graph Model; 2014 Sep; 53():148-160. PubMed ID: 25137647
[TBL] [Abstract][Full Text] [Related]
18. Molecular interaction fingerprint approaches for GPCR drug discovery.
Vass M; Kooistra AJ; Ritschel T; Leurs R; de Esch IJ; de Graaf C
Curr Opin Pharmacol; 2016 Oct; 30():59-68. PubMed ID: 27479316
[TBL] [Abstract][Full Text] [Related]
19. Identification of residues involved in neurotensin binding and modeling of the agonist binding site in neurotensin receptor 1.
Barroso S; Richard F; Nicolas-Ethève D; Reversat JL; Bernassau JM; Kitabgi P; Labbé-Jullié C
J Biol Chem; 2000 Jan; 275(1):328-36. PubMed ID: 10617622
[TBL] [Abstract][Full Text] [Related]
20. The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach.
Fan Y; Lai MH; Sullivan K; Popiolek M; Andree TH; Dollings P; Pausch MH
Bioorg Med Chem Lett; 2008 Nov; 18(21):5789-91. PubMed ID: 18849166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
